Tag: relief

SAN DIEGO, Aug. 03, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, both dates inclusive (the “Class Period”), have until Monday, August 25, 2025 to seek appointment as lead plaintiff of the Hims & Hers class action lawsuit. Captioned Sookdeo v. Hims & Hers Health, Inc., No. 25-cv-05315 (N.D. Cal.), the Hims & Hers class action lawsuit charges Hims & Hers and certain of Hims & Hers’ executives with violations of the Securities Exchange Act of 1934. A subsequently filed complaint is captioned Yaghsizian v. Hims & Hers Health, Inc., No. 25-cv-05321 (N.D. Cal.).

In a year defined by holistic health trends, anti-inflammatory nutrition stacks, and consumer-led demand for clean-label routines, Pilly Labs is emerging as a go-to gummy supplement brand for wellness seekers prioritizing transparency and convenience. With turmeric, mushroom extracts, and collagen continuing to dominate 2025’s ingredient interest charts, Pilly Labs’ natural formulations are gaining traction across TikTok rituals, Google search trends, and Reddit supplement stacks — not as prescriptions, but as daily wellness additions for those exploring inflammation support and whole body vitality.

As 2025 consumers increasingly seek natural ways to support attention, emotional balance, and metabolic wellness, Pilly Labs introduces a fruiting body mushroom gummy blend featuring Lion’s Mane, Reishi, and Cordyceps—positioned at the intersection of convenience, cognitive clarity, and ingredient transparency.

Interest in Chaga mushroom supplements is surging across 2025 wellness trends, as consumers seek cleaner, science-aligned alternatives for immune support, inflammation balance, and energy recovery. With dual-extracted fruiting body sourcing and lab-tested transparency, Pilly Labs’ latest formula is gaining attention as a serious contender in the adaptogenic mushroom space—without the hype or filler.

As consumers search for natural alternatives to support focus, immune resilience, and metabolic balance, mushroom gummies are rapidly emerging as a preferred delivery method—especially in 2025’s ingredient-first supplement movement led by fruiting body extracts like Chaga, Lion’s Mane, and Cordyceps.

New 5-Minute Routine May Help Naturally Support Knee Cartilage Health, Flexibility, and Joint Comfort at Any Age

Experts Reveal 2025 Dog Gut Health Findings, Ingredient Transparency Push, and the Rise of Targeted Canine Probiotics

Discover the official launch of Arialief in United States, UK, NZ, Canada and Australia, a new supplement developed to support those suffering from neuropathy and sciatic nerve discomfort. Learn how this science-backed formulation aims to provide natural relief and improve nerve health.

Inspired by the success of Audifort Drops, Audizen Drops are now officially launched in the United States, UK, NZ, Canada, and Australia. This natural Tinnitus formula supports hearing clarity and offers targeted relief from tinnitus symptoms.

NexZen Extracts, a premium name in hemp-derived cannabinoid products, has been officially recognized as the Choice of THCA flower brand of 2025

SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fiserv, Inc. (NYSE: FI) common stock between July 24, 2024 and July 22, 2025, inclusive (the “Class Period”), have until September 22, 2025 to seek appointment as lead plaintiff of the Fiserv class action lawsuit. Captioned City of Hollywood Police Officers’ Retirement System v. Fiserv, Inc., No. 25-cv-06094 (S.D.N.Y.), the Fiserv class action lawsuit charges Fiserv as well as certain of Fiserv’s top current and former executives with violations of the Securities Exchange Act of 1934.

SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Lockheed Martin Corporation (NYSE: LMT) securities between January 23, 2024 and July 21, 2025, both dates inclusive (the “Class Period”), have until September 26, 2025 to seek appointment as lead plaintiff of the Lockheed Martin class action lawsuit. Captioned Khan v. Lockheed Martin Corporation, No. 25-cv-06197 (S.D.N.Y.), the Lockheed Martin class action lawsuit charges Lockheed Martin and certain of Lockheed Martin’s top current and former executives with violations of the Securities Exchange Act of 1934.